Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies

Biochemical and Biophysical Research Communications

Volumn 397, Issue 3, 2010, Pages 580-585

  Du, Lanying ^a   Zhao, Guangyu ^b   Zhang, Xiujuan ^a   Liu, Zhonghua ^a   Yu, Hong ^b   Zheng, Bo Jian ^c   Zhou, Yusen ^b   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hemagglutinin; Influenza A virus; Monoclonal antibodies; Pseudovirus neutralization assay

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSAFETY; CLADISTICS; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPIDEMIC; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; TARGET CELL; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS;

AVES; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA A VIRUS; SUIDAE;

EID: 77954213672     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.161     Document Type: Article

References (28)

1. Smith G.J., Vijaykrishna D., Bahl J., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
2. Neumann G., Chen H., Gao G.F., et al. H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 2010, 20:51-61.
3. Russell R.J., Kerry P.S., Stevens D.J., et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA 2008, 105:17736-17741.
4. Li Z.N., Lee B.J., Langley W.A., et al. Length requirements for membrane fusion of influenza virus hemagglutinin peptide linkers to transmembrane or fusion peptide domains. J. Virol. 2008, 82:6337-6348.
5. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
6. Tompkins S.M., Lin Y., Leser G.P., et al. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 2007, 362:139-150.
7. Kodihalli S., Goto H., Kobasa D.L., et al. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 1999, 73:2094-2098.
8. Treanor J.J., Schiff G.M., Hayden F.G., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
9. Lim A.P., Chan C.E., Wong S.K., et al. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol. J. 2008, 5:130.
10. Hanson B.J., Boon A.C., Lim A.P., et al. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 2006, 7:126.
11. Friesen R.H., Koudstaal W., Koldijk M.H., et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010, 5:e9106.
12. Martinez O., Tsibane T., Basler C.F. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int. Rev. Immunol. 2009, 28:69-92.
13. Simmons C.P., Bernasconi N.L., Suguitan A.L., et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007, 4:e178.
14. Prabakaran M., Prabhu N., He F., et al. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 2009, 4:e5672.
15. Maneewatch S., Thanongsaksrikul J., Songserm T., et al. Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir. Ther. 2009, 14:221-230.
16. Yoshida R., Igarashi M., Ozaki H., et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 2009, 5:e1000350.
17. Krause J.C., Tumpey T.M., Huffman C.J., et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J. Virol. 2010, 84:3127-3130.
18. Han D.P., Kim H.G., Kim Y.B., et al. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004, 326:140-149.
19. Zhang S., Xiao L., Zhou H., et al. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus. J. Virol. Methods 2008, 154:99-103.
20. Alberini I., Del T.E., Fasolo A., et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009, 27:5998-6003.
21. Guo Y., Rumschlag-Booms E., Wang J., et al. Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza. Virol. J. 2009, 6:39.
22. He Y., Lu H., Siddiqui P., et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 2005, 174:4908-4915.
23. Du L., Zhao G., Chan C.C., et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009, 393:144-150.
24. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
25. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
26. Nayak B., Kumar S., DiNapoli J.M., et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 2010, 84:2408-2420.
27. Garcia J.M., Pepin S., Lagarde N., et al. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 2009, 4:e7918.
28. Sun L., Lu X., Li C., et al. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 2009, 4:e5476.